Nirsevimab (Beyfortus) for RSV Prevention in Infants
The short answer
Nirsevimab (brand name Beyfortus) is a monoclonal antibody recommended by the CDC and AAP for all infants under 8 months entering their first RSV season, and for certain high-risk children aged 8-19 months entering their second season. Unlike palivizumab (Synagis), which required monthly injections and was limited to high-risk infants, nirsevimab is a single injection that provides protection for an entire RSV season. It is not a vaccine but provides ready-made antibodies that protect against severe RSV disease.
Thousands of parents search for this exact thing. You are not alone.
By Age
What to expect by age
0-8 months (first RSV season)
All infants under 8 months old entering their first RSV season are recommended to receive nirsevimab. The injection can be given shortly after birth (for babies born during RSV season, typically October through March in most of the US) or before the start of RSV season for babies born earlier. It is a single intramuscular injection that provides approximately 5 months of protection. Nirsevimab can be given alongside routine childhood vaccines. The most common side effect is mild injection site reaction.
8-19 months (second RSV season)
Nirsevimab is recommended for a second season only for children at increased risk of severe RSV, including those born prematurely (before 32 weeks), those with chronic lung disease of prematurity requiring medical treatment in the past 6 months, those with hemodynamically significant congenital heart disease, those who are severely immunocompromised, or children with certain neuromuscular conditions. If your child falls into one of these categories, discuss a second-season dose with your pediatrician.
During RSV season
RSV season typically runs from October through March in most parts of the United States, though timing varies by region. Nirsevimab should ideally be given just before or at the start of RSV season for maximum protection during peak circulation. If your baby is born during RSV season, they should receive nirsevimab before hospital discharge if possible. The protection lasts approximately five months, which covers the typical RSV season duration. If nirsevimab is unavailable, palivizumab remains an alternative for qualifying high-risk infants.
What Should You Do?
When to take action
- Your baby receives nirsevimab and has no reaction or a mild injection site reaction
- Your baby receives nirsevimab alongside other routine vaccines without issues
- Your baby still gets a mild cold during RSV season despite receiving nirsevimab (it prevents severe disease, not all infection)
- You want to discuss whether your baby qualifies for nirsevimab
- Your older infant has risk factors and you want to discuss second-season dosing
- You are unsure of your local RSV season timing and want to know the best time for the injection
- Your baby had a reaction to the injection that concerns you
- Your baby has a severe allergic reaction after receiving nirsevimab: hives, facial swelling, difficulty breathing - call 911
- Your baby develops signs of severe RSV despite receiving nirsevimab: breathing difficulty, blue skin color, apnea, refusal to feed
Sources
Related Resources
Trust your instincts. If something feels wrong, reach out to your pediatrician.
Worrying about your baby means you care. That is a good thing.
Related Medical Concerns
RSV in Babies: What to Know
RSV (respiratory syncytial virus) is a common virus that affects nearly all children by age 2. Most babies have mild cold-like symptoms, but some, especially young infants and those with underlying conditions, can develop breathing difficulties. Watch for fast breathing, flaring nostrils, or visible chest pulling - these are signs to seek medical care.
RSV Bronchiolitis: When Does a Baby Need the Hospital
Most babies with RSV bronchiolitis can be managed at home with supportive care, but about 1-3% of infected infants require hospitalization. Key indicators for seeking emergency care include persistent oxygen saturation below 90%, significant difficulty breathing (chest retractions, nasal flaring, grunting), inability to feed, signs of dehydration, or apnea (pauses in breathing). Babies under 3 months, premature infants, and those with chronic lung or heart disease are at highest risk for severe disease.
Premature Baby Immune System: Protecting Your Preemie
Premature babies have less mature immune systems than full-term infants because they missed out on maternal antibodies that transfer most actively during the third trimester of pregnancy. This makes them more susceptible to infections, particularly respiratory illnesses like RSV and influenza. Protective measures include limiting visitors, practicing strict hand hygiene, keeping up with vaccinations on the chronological (not adjusted) age schedule, and considering RSV immunization with nirsevimab.
My Baby's Head Shape Looks Abnormal
Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.
Achondroplasia (Dwarfism) in Babies
Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.
Adenoid Hypertrophy and Breathing
Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.